Overview

Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the effects of intravitreal ranibizumab (IVR) as adjunctive treatment for trabeculectomy with mitomycin C (TMC) in neovascular glaucoma (NVG).
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Siriraj Hospital
Treatments:
Mitomycin
Ranibizumab
Criteria
Inclusion Criteria:

- Consecutive patients with neovascular glaucoma

- Age more than 80 year old

- Provide written informed consent

Exclusion Criteria:

- Un-cooperated patients